Duane Reade Q3
This article was originally published in The Rose Sheet
Executive Summary
Sales for the third quarter were up 8.2% to $338.6 mil., approximately $11.4 mil. below the company's previous expectations due to economic weakness and slowing growth rate of the prescription sector, retailer announces Oct. 6. The announcement was made ahead of an Oct. 23 Q3 earnings call. Northeast power outage in August resulted in a sales loss of about $3.3 mil., the firm notes. Same store sales for the period improved 3%, with pharmacy same store sales increasing 8.6% and front-end same store sales declining 1.1%. Sales performance during Q3 combined with economic impact have lowered net income to about $.08-$.09 per diluted share versus original expectations of $.15-$.20 per diluted share, retailer adds. Annual sales are now expected to be about $1.39 bil., while diluted EPS will be between $.55-$.61...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.